Allogeneic Stem Cell Transplantation for Multiple Myeloma

Hematology/Oncology Clinics of North America

Volumn 28, Issue 5, 2014, Pages 891-902

  Bensinger, William ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allogeneic stem cell transplant; Autologous stem cell transplant; Multiple myeloma; Myeloablative transplant; Nonmyeloablative transplant; Peripheral blood stem cells

Indexed keywords

BORTEZOMIB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; THIOTEPA; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; GRAFT VERSUS HOST REACTION; HUMAN; MULTIPLE MYELOMA; REDUCED INTENSITY CONDITIONING; REVIEW; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; PROCEDURES; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84912530935     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.06.001     Document Type: Review

References (51)

1. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. JClin Oncol 2008, 26:480-492.
2. Thomas E.D., Lochte H.L., Lu W.C., et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. NEngl J Med 1957, 257:491-496.
3. Higby D.J., Brass C., Fitzpatick J., et al. Bone marrow transplantation in multiple myeloma: a case report with protein studies. ASCO Abstracts 1982, 192:C-747.
4. Ozer H., Han T., Nussbaum-Blumenson A., et al. Allogeneic BMT and idiotypic monitoring in multiple myeloma. AACR Abstracts 1984, 84:161.
5. Buckner C.D., Fefer A., Bensinger W.I., et al. Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle Experience. Eur J Haematol 1989, 43:186-190.
6. Gahrton G., Tura S., Flesch M., et al. Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for bone marrow transplantation. Blood 1987, 69:1262-1264.
7. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88:2787-2793.
8. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. JClin Oncol 2006, 24:929-936. [Erratum appears in J Clin Oncol 2006;24(17):2687].
9. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
10. Kröger N., Badbaran A., Zabelina T., et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013, 19(3):398-404.
11. Björkstrand B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma - a retrospective case-matched study from the European Group for Blood and Marrow transplantation. Blood 1996, 88:4711-4718.
12. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009, 115:4715-4726.
13. Gahrton G., Svensson H., Cavo M., et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209-216.
14. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
15. Champlin R., Khouri I., Kornblau S., et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 1999, 13:1041-1057. [review].
16. Verdonck L.F., Petersen E.J., Lokhorst H.M., et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998, 22:1057-1063.
17. Bruno B., Rotta M., Patriarca F., et al. Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009, 113:3375-3382.
18. Rotta M., Storer B.E., Sahebi F., et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009, 113:3383-3391.
19. Gerull S., Goerner M., Benner A., et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005, 36:963-969.
20. Kroger N., Perez-Simon J.A., Myint H., et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004, 10:698-708.
21. Lee C.K., Badros A., Barlogie B., et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003, 31:73-80.
22. Mohty M., Boiron J.M., Damaj G., et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:77-84.
23. Majolino I., Davoli M., Carnevalli E., et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007, 48:759-766.
24. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005, 105:4532-4539.
25. Ringdén O., Shrestha S., da Silva G.T., et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012, 47:831-837.
26. Bensinger W., Rotta M., Storer B., et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012, 47:1312-1317.
27. Patriarca F., Einsele H., Spina F., et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant 2012, 18(4):617-626.
28. Sonneveld P., Schmidt-Wolf I.G., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. JClin Oncol 2012, 30(24):2946-2955.
29. Knop S., Liebisch P., Hebart H., et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma- an interim analysis of the German DSMM V Trial. Blood 2009, 114:22.
30. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
31. Bruno B., Rotta M., Patriarca F., et al. Acomparison of allografting with autografting for newly diagnosed myeloma. NEngl J Med 2007, 356:1110-1120.
32. Giaccone L., Storer B., Patriarca F., et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011, 117:6721-6727.
33. Rosinol L., Perez-Simon J.A., Sureda A., et al. Aprospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
34. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
35. Bjorkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. JClin Oncol 2011, 29:3016-3022.
36. Gahrton G., Iacobelli S., Bjorkstrand B., et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013, 121:5055-5063.
37. Lokhorst H.M., van der Holt B., Cornelissen J.J., et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012, 119:6219-6225.
38. Kharfan-Dabaja M.A., Hamadani M., Reljic T., et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. JHematol Oncol 2013, 6:2.
39. Donato M.L., Siegel D.S., Vesole D.H., et al. Long-term follow-up of patients with multiple myeloma who received allogeneic hemaotpoietic stem cell transplantation. Blood 2013, 122:2154.
40. Sahebi F., Iacobelli S., Van Biezen A., et al. Reduced intensity allogeneic stem cell transplant in patients with multiple myeloma: a comparison of planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) as upfront transplant in patients with multiple myeloma, an EBMT analysis. Blood 2013, 122:920.
41. Ghosh N., Ye X., Bolaños-Meade J., et al. Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) in multiple myeloma with post-transplantation cyclophosphamide. Blood 2013, 122:3407.
42. Lokhorst H., van der Holt B., Cornelissen J., et al. No improvement of overall survival after extended follow-up of donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50/54 study. Blood 2013, 122:2132.
43. Moreau P. Death of frontline allo-SCT in myeloma. Blood 2012, 119(26):6178-6179.
44. Dispenzieri A., Wiseman G.A., Lacy M.Q., et al. APhase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 2010, 85:409-413.
45. Orozco J.J., Zeller J., Pagel J.M. Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Ther Adv Hematol 2012, 3:5-16.
46. Caballero-Velázquez T., López-Corral L., Encinas C., et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol 2013, 162(4):474-482.
47. Bensinger W.I., Green D.J., Burwick N., et al. Aprospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. Bone Marrow Transplant 2014, 49(4):492-495. 10.1038/bmt.2013.219.
48. El-Cheikh J., Crocchiolo R., Furst S., et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol 2012, 40:521-527.
49. Kwak L.W., Taub D.D., Duffey P.L., et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345:1016-1020.
50. de Weers M., Tai Y.T., van der Veer M.S., et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. JImmunol 2011, 186(3):1840-1848.
51. Mavroudis D.A., Dermime S., Molldrem J., et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 1998, 101(3):565-570.